A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Phase of Trial: Phase III
Latest Information Update: 16 Jan 2018
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Olmesartan medoxomil
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 16 Jan 2018 Status changed from completed to discontinued, according to results published in the Journal of Clinical Hypertension (Greenwich).
- 16 Jan 2018 Results published in the Journal of Clinical Hypertension (Greenwich)
- 14 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.